ISSUE #14 Nov 12, 2025
🔔Don't Miss Out! Global IR @JPM 2026 is Coming!
Mark your calendar for this premier global pitching and networking event,
held during the JP Morgan Healthcare Conference.
Global IR @JPM 2026 is proudly co-hosted by KoreaBIO, Sidley Austin LLP, and BioCentury.
      ✔️ For Companies: We are currently accepting applications for pitching. Show your interest now!
      ✔️ For Attendees: Online registration will open at the end of November.
The 20th Bio Networking Event,
co-hosted by KoreaBIO and Samsung Bioepis, brought together over 300 biotech professionals!
🎬 Experience the energy of
BIOPLUS-INTERPHEX KOREA 2025
through our highlight video!
*English subtitles available
∎ ABL spinout Neok exits stealth with $75M to take bispecific ADCs into the clinic- Fierce Biotech
∎ Celltrion Completes Merger Review for Acquisition of Lilly's U.S. Manufacturing Facility - The Asia Business Daily
∎ Cha Biotech’s Matica Bio, Calidi partner on cancer immunotherapy project - The Korea Herald
∎ Hanmi Pharmaceutical receives U.S. FDA approval for phase 1 trial of the world’s first muscle-boosting obesity drug candidate - THE BIO
∎ Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO - BioSpace
∎ South Korea’s Celltrion Inks $744 Million Deal with U.S. Biotech, Eyeing Autoimmune Drug Market - GeneOnline
∎ SK bioscience Q3 sales nearly tripled thanks to greater contribution by German offshoot - KBR
∎ Study finds proteins precisely control direction of cell movement - The Dong-A Ilbo
∎ Naver and Nvidia to Develop Next-Generation 'Physical AI' Platform for Industrial Applications - The Asia Business Daily
∎ Curocell inks supply deal with ProBio for viral vectors key to CAR-T production - KBR
∎ Hanmi’s Epiglenatide Achieves Strong Phase III Results, Targets 2026 Launch - Hitnews
∎ Hanmi Pharmaceutical signs supply agreement with Vietnam’s Viet-Phap for finished hypertension combination drug - THE BIO
∎ Korea's young pharma breed Samsung Biologics and Celltrion bulk up as bottom line holds - Aju Press
∎ Korea trio targets 10 AI-designed antibody candidates in 27 months - Chosun Biz
∎ Ligachem Bio Receives FDA Approval to Add High-Dose Cohort to LNCB74 Phase 1 Clinical Trial - The Asia Business Daily
∎ Numerous Genetic Factors for Alzheimer's Identified in Koreans... Foundation Laid for Precision Personalized Treatment - The Asia Business Daily
∎ PharmAbcine Announces Korean Patent Grant for TIE2-Activating Antibody PMC-403 - THE BIO
∎ S. Korea to invest over 900 bln won to develop 'game-changers' in medical device sector - Yonhap News Agency
∎ South Korea launches medical and bio-specialized AI foundation model projects - The Korea Post
📰
Join our press list
Get KoreaBIO updates
& media resources
💬
Share Your thoughts!
How was your letter today?
✉️
Korean Newsletter
Daily biotech news from Korea and around the world
— in Korean
Explore More
KoreaBIO (Korea Biotechnology Industry Organization)
700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
+82-31-628-0037
수신거부 Unsubscribe